Rohit Loomba

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4715673/publications.pdf

Version: 2024-02-01

61 papers	3,383 citations	201674 27 h-index	182427 51 g-index
61 all docs	61 docs citations	61 times ranked	2986 citing authors

#	Article	IF	Citations
1	Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease. Gut, 2022, 71, 983-990.	12.1	45
2	Magnetic resonance elastography plus Fibrosisâ€4 versus FibroScanâ€“aspartate aminotransferase in detection of candidates for pharmacological treatment of NASHâ€related fibrosis. Hepatology, 2022, 75, 661-672.	7.3	29
3	Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus. Hepatology Communications, 2022, 6, 461-472.	4.3	10
4	Advancing the global public health agenda for NAFLD: a consensus statement. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 60-78.	17.8	330
5	Utilizing Macrosteatotic Allografts for Nonalcoholic Steatohepatitis Recipients. Liver Transplantation, 2022, 28, 552-553.	2.4	0
6	Noninvasive Risk Stratification for Nonalcoholic Fatty Liver Disease Among Living Liver Donor Candidates: A Proposed Algorithm. Liver Transplantation, 2022, 28, 670-677.	2.4	3
7	NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH. Hepatology, 2022, 76, 172-185.	7.3	24
8	Non-Invasive Biomarkers of Nonalcoholic Steatohepatitis: the FNIH NIMBLE project. Nature Medicine, 2022, 28, 430-432.	30.7	33
9	Longitudinal association of magnetic resonance elastographyâ€associated liver stiffness with complications and mortality. Alimentary Pharmacology and Therapeutics, 2022, 55, 292-301.	3.7	38
10	Comparative efficacy of an optimal exam between ultrasound versus abbreviated <scp>MRI</scp> for <scp>HCC</scp> screening in <scp>NAFLD</scp> cirrhosis: A prospective study. Alimentary Pharmacology and Therapeutics, 2022, 55, 820-827.	3.7	30
11	Review article: current and emerging therapies for the management of cirrhosis and its complications. Alimentary Pharmacology and Therapeutics, 2022, 55, 1099-1115.	3.7	20
12	Metaâ€analysis: analysis of mechanistic pathways in the treatment of <scp>nonâ€alcoholic</scp> steatohepatitis. Evidence from a Bayesian network <scp>metaâ€analysis</scp>. Alimentary Pharmacology and Therapeutics, 2022, 55, 1076-1087.	3.7	15
13	Metaâ€analysis: prevalence of, and risk factors for, nonâ€alcoholic fatty liver disease in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2022, 55, 894-907.	3.7	32
14	Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (<scp>NAFLD</scp>). Alimentary Pharmacology and Therapeutics, 2022, 55, 1441-1451.	3.7	9
15	Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score. Hepatology, 2022, 76, 1150-1163.	7.3	15
16	Direct Comparison of Quantitative US versus Controlled Attenuation Parameter for Liver Fat Assessment Using MRI Proton Density Fat Fraction as the Reference Standard in Patients Suspected of Having NAFLD. Radiology, 2022, , 211131.	7.3	12
17	Editorial: screening for hepatocellular carcinoma in <scp>NAFLD</scp> cirrhosisâ€”towards abbreviated <scp>MRI</scp> alternative in patients with obesity? Authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 55, 1212-1213.	3.7	0
18	Prognostic utility of magnetic resonance elastography and MEFIB index in predicting liver-related outcomes and mortality in individuals at risk of and with nonalcoholic fatty liver disease. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482210938.	3.2	18

#	Article	IF	Citations
19	Letter: nonâ€invasive prediction models to exclude cirrhosis in <scp>NAFLD</scp> â€"not everyone fits the mould. Authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 56, 182-183.	3.7	0
20	MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis. Gut, 2021, 70, 1946-1953.	12.1	78
21	The Commensal Microbe V eillonella as a Marker for Response to an FGF19 Analog in NASH. Hepatology, 2021, 73, 126-143.	7.3	58
22	Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 223-238.	17.8	867
23	Hepatic Fibrosis Associates With Multiple Cardiometabolic Disease Risk Factors: The Framingham Heart Study. Hepatology, 2021, 73, 548-559.	7.3	49
24	NAFLD: Reporting Histologic Findings in Clinical Practice. Hepatology, 2021, 73, 2028-2038.	7.3	86
25	rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis. Journal of Hepatology, 2021, 74, 20-30.	3.7	77
26	Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases. Annals of Laboratory Medicine, 2021, 41, 16-24.	2.5	27
27	Emerging Metabolic and Transcriptomic Signature of PNPLA3â€Associated NASH. Hepatology, 2021, 73, 1248-1250.	7.3	3
28	The impact of genetic risk on liver fibrosis in nonâ€alcoholic fatty liver disease as assessed by magnetic resonance elastography. Alimentary Pharmacology and Therapeutics, 2021, 54, 68-77.	3.7	18
29	Financial Hardship From Medical Bills Among Adults With Chronic Liver Diseases: National Estimates From the United States. Hepatology, 2021, 74, 1509-1522.	7.3	9
30	Systematic review with network metaâ€analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH. Alimentary Pharmacology and Therapeutics, 2021, 54, 880-889.	3.7	51
31	Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with nonâ€alcoholic fatty liver disease assessed by magnetic resonance imaging. Alimentary Pharmacology and Therapeutics, 2021, 54, 1150-1161.	3.7	79
32	Emerging Role of Genomic Analysis in Clinical Evaluation of Lean Individuals With NAFLD. Hepatology, 2021, 74, 2241-2250.	7.3	41
33	Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferatorâ€activated receptor Î± modulator (SPPARMÎ±), versus placebo in patients with nonâ€alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2021, 54, 1263-1277.	3.7	90
34	Links between gut microbiome composition and fatty liver disease in a large population sample. Gut Microbes, 2021, 13, 1-22.	9.8	41
35	Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with nonâ€alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2021, 53, 1030-1037.	3.7	40
36	Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial. Nature Medicine, 2021, 27, 1825-1835.	30.7	98

#	Article	IF	Citations
37	Editorial: evolution of GLPâ€1 receptor agonists as pharmacotherapy for NASH beyond diabetes mellitus and obesity â€“ authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2021, 54, 1498-1498.	3.7	0
38	A small molecule targeting ALOX12-ACC1 ameliorates nonalcoholic steatohepatitis in mice and macaques. Science Translational Medicine, 2021, 13, eabg8116.	12.4	30
39	Multiple omics study identifies an interspecies conserved driver for nonalcoholic steatohepatitis. Science Translational Medicine, 2021, 13, eabg8117.	12.4	23
40	Editorial: liver stiffness by magnetic resonance elastography and cardiovascular risk in nonâ€alcoholic fatty liver diseaseâ€”simply associated or more complicated? Authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 53, 1230-1231.	3.7	0
41	Clinical Research in Hepatology in the COVIDâ€19 Pandemic and Postâ€Pandemic Era: Challenges and the Need for Innovation. Hepatology, 2020, 72, 1819-1837.	7.3	17
42	Elevated Glycated Hemoglobin Is Associated With Liver Fibrosis, as Assessed by Elastography, in a Populationâ€Based Study of Mexican Americans. Hepatology Communications, 2020, 4, 1793-1801.	4.3	17
43	Editorial: how widespread and serious is nonâ€alcoholic fatty liver disease in the real world? Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 51, 1200-1201.	3.7	0
44	Review article: the emerging role of genetics in precision medicine for patients with nonâ€alcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics, 2020, 51, 1305-1320.	3.7	103
45	Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data. Alimentary Pharmacology and Therapeutics, 2020, 51, 1149-1159.	3.7	101
46	Plasma eicosanoids as noninvasive biomarkers of liver fibrosis in patients with nonalcoholic steatohepatitis. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482092390.	3.2	24
47	Advances in non-invasive assessment of hepatic fibrosis. Gut, 2020, 69, 1343-1352.	12.1	179
48	Collagen biology and nonâ€invasive biomarkers of liver fibrosis. Liver International, 2020, 40, 736-750.	3.9	107
49	Multicenter Validation of Association Between Decline in MRIâ€PDFF and Histologic Response in NASH. Hepatology, 2020, 72, 1219-1229.	7.3	79
50	Have incidence rates of liver cancer peaked in the United States?. Cancer, 2020, 126, 3151-3155.	4.1	26
51	Editorial: evolving histological assessment of NASH. Authors' reply. Alimentary Pharmacology and Therapeutics, 2019, 50, 1245-1246.	3.7	0
52	Letter: probiotics? Yes, but which ones? Authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2019, 50, 968-968.	3.7	0
53	Standardising the interpretation of liver biopsies in nonâ€alcoholic fatty liver disease clinical trials. Alimentary Pharmacology and Therapeutics, 2019, 50, 1100-1111.	3.7	27
54	Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications. Alimentary Pharmacology and Therapeutics, 2019, 50, 144-158.	3.7	50

#	Article	IF	Citations
55	Serum bile acid patterns are associated with the presence of NAFLD in twins, and doseâ€dependent changes with increase in fibrosis stage in patients with biopsyâ€proven NAFLD. Alimentary Pharmacology and Therapeutics, 2019, 49, 183-193.	3.7	80
56	Clinical and metabolic effects associated with weight changes and obeticholic acid in nonâ€alcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics, 2018, 47, 645-656.	3.7	54
57	Differential Activation of Hepatic Invariant NKT Cell Subsets Plays a Key Role in Progression of Nonalcoholic Steatohepatitis. Journal of Immunology, 2018, 201, 3017-3035.	0.8	69
58	Editorial: role of leucineâ€metforminâ€sildenafil combination inÂthe treatment of nonalcoholic fatty liver disease (<scp>NAFLD</scp>). Alimentary Pharmacology and Therapeutics, 2018, 48, 378-379.	3.7	1
59	Assessment of treatment response in nonâ€alcoholic steatohepatitis using advanced magnetic resonance imaging. Alimentary Pharmacology and Therapeutics, 2017, 45, 844-854.	3.7	21
60	Editorial: further evidence for the use of advanced magnetic resonance imaging techniques to monitor <scp>NAFLD</scp> â€“ authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2017, 45, 1271-1272.	3.7	0
61	Editorial: nonâ€alcoholic fatty liver diseaseâ€a pandemic in need of novel treatments and endpoints. Alimentary Pharmacology and Therapeutics, 2017, 46, 65-66.	3.7	0